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Patients with large benign goiters often present local compressive symptoms that 
require surgical treatment, including dysphagia, neck tightness, and airway obstruction. 
In contrast, patients with such goiters who remain asymptomatic may be observed 
after exclusion of malignancy. The use of levothyroxine (LT4) to reduce the volume of 
the goiter is still a controversial treatment for large goiters, and the optimal surgical 
procedure for multinodular goiter is still debatable. Radioiodine is a safe and effective 
treatment option when used alone or in combination with recombinant human TSH. 
This review discusses current therapeutic options to treat diffuse and multinodular non-
toxic benign goiters.
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iNTRODUCTiON
Once the diagnosis of non-toxic diffuse goiter (NDG) or non-toxic nodular goiter (NNG) is estab-
lished, the following management goals should be considered:
 a. Correct the underlying thyroid dysfunction, if present;
 b. Verify if the goiter is growing or causing obstructive symptoms;
 c. Exclude malignancy if one or more nodules are suspicious;
 d. Determine whether the goiter requires therapy, and if so, weight the benefits and risks of medical 
and surgical interventions and reach a decision with the patient about what type of treatment 
should be administered.
The expression of the progressive and nodular increase of the thyroid in non-toxic benign goiters 
is the result of a combination of genetic and environmental factors, of which iodine deficiency is 
the most important (1). The treatment of benign non-toxic goiter is a challenge for clinicians and 
endocrinologists. Similarly to how patients with single thyroid nodules are assessed, all individuals 
with benign non-toxic goiter must undergo careful evaluation with serum TSH measurement and 
thyroid ultrasonography to guide the selection of the nodule (or nodules) to be biopsied (2). After 
exclusion of malignancy, treatment should be considered for individuals with compression of local 
structures, cosmetic concerns, and/or thyroid hyperfunction (2). The choice of treatment in patients 
with benign non-toxic goiter can be challenging, considering that the size of the goiter and the 
occurrence of symptoms often follow a non-linear association (Table 1).
TABLe 1 | Treatment choices reported by ATA, eTA, and LATS members 
based on an index case of a patient with a simple non-toxic nodular 
goiter, without suspicion of malignancy.
Therapy Non-toxic nodular goiter
ATA (n = 140) eTA (n = 120) LATS (n = 148)
None 36 28 39
Levothyroxine 56 52 21
Radioiodinea 1 6 7
Surgery 6 10 28
The numbers correspond to the percentage of organization members who responded 
to the questionnaire.
ATA, American Thyroid Association; ETA, European Thyroid Association; LATS, Latin 
American Thyroid Association.
Adapted from Ref. (3).
aIncludes both isolated radioiodine use and radioiodine associated with rhTSH.
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Non-Toxic Diffuse Goiter
There is no ideal therapy for NDGs (4), but for patients requiring 
treatment, clinical management is the most frequent choice. It is 
unclear whether or not early treatment of NDGs can inhibit the 
development of nodular goiter.
The development of NDGs occurs from a combination of 
genetic and environmental factors. Prolonged TSH stimulation, 
which frequently occurs in association with iodine deficiency, has 
an important role in thyroid enlargement. In these circumstances, 
iodine supplementation would be an adequate approach (400 μg 
of iodine for 8–12 months). A significant reduction in goiter size 
has been observed in patients with NDG supplemented with 
iodine (5, 6). In fact, supplementation with iodine 400 μg/day has 
been demonstrated to be as effective as suppressive therapy with 
LT4 150 μg/day (5). However, except in a few European countries, 
iodine is no longer used for the treatment of benign non-toxic 
goiter.
In contrast, a beneficial effect of LT4 has been shown in NDG 
(7). A volume reduction of 50% or more was detected in 31% 
(11/35) of the patients after 6 months (7). If suppressive treatment 
is considered, then administration of thyroid hormone in enough 
doses to inhibit or reduce TSH secretion may be used. However, 
it should be considered that the volume of the goiter returns to 
pretreatment size after LT4 withdrawal. As may be expected, 
many thyroid experts are unenthusiastic about treating NDG, 
although others advocate the use of LT4 favoring the notion that 
early treatment may prevent later development of nodular goiter. 
As with any issue in clinical medicine, the benefits of such therapy 
must be weighed against the potential risks of TSH suppression.
Regarding radioiodine therapy in NDG, two earlier small 
uncontrolled studies are available (8, 9). In the first study, 11 
patients with symptoms of pressure and cosmetic complaints 
were selected for radioiodine ablation after refusing surgical 
treatment. The mean thyroid volume reduction achieved with 
a single dose of radioiodine within the first year was 62%, and 
2 of the 11 patients (18%) developed hypothyroidism (8). In 
another study, 10 patients were treated with radioiodine and 
were followed up for 18  months with measurements of the 
thyroid volume by ultrasonography. The volume declined by 
50% within 12–18  months. During follow-up, one patient 
(10%) developed persistent hypothyroidism and another (who 
presented positive antithyroperoxidase levels) developed tran-
sient hypothyroidism (9).
Non-Toxic Nodular Goiter
The ideal treatment for NNG is controversial (Table 1) (3), in part 
due to the variation in the natural history of these goiters. Some 
patients present an enlargement in goiter size with time along 
with the development of nodules, symptoms of compression, and 
cosmetic reasons (10). In contrast, the enlargement of the goiter 
may become stable or reduce spontaneously with time in around 
20% of the women and 5% of the men (11).
Current alternatives for NNG treatment include
•	 Clinical observation for asymptomatic patients;
•	 Thyroid hormone suppressive therapy;
•	 Radioiodine therapy alone or preceded by recombinant human 
TSH (rhTSH); and
•	 Surgery.
Among these options, treatment is chosen individually for 
each patient in view of the risks, benefits, and availability of the 
various techniques, experience of the treating physician, and 
patient’s personal preference (Table 2).
CLiNiCAL OBSeRvATiON
Clinical observation, including thyroid function monitoring and 
ultrasonographic assessment at regular intervals, is an alternative 
in cases of small goiters not causing compressive symptoms and 
associated with normal thyroid function. If clinical observation 
is chosen, the possibility of malignancy should be excluded 
by fine-needle aspiration biopsy (FNAB) that is guided by 
ultrasonography.
Asymptomatic euthyroid patients with benign non-toxic 
goiter and without cosmetic symptoms may be simply observed 
with clinical and laboratory evaluation and thyroid imaging tests. 
In most cases, patients with asymptomatic NNG may be evalu-
ated yearly with careful thyroid palpation and measurement of 
serum TSH level. Ultrasonography may be performed when the 
palpation of the thyroid is uncertain, whereas nodules that appear 
to enlarge should be evaluated with FNAB. Evaluation with neck 
computed tomography or magnetic resonance imaging (MRI) 
may be required when the goiter is subesternal.
The American Thyroid Association recommends a standard 
follow-up interval of 6–18 months for patients with NNG, which 
may be gradually prolonged if no substantial changes are observed 
during the first 3–5 years (12).
SUPPReSSive THeRAPY wiTH 
LevOTHYROXiNe
Although LT4 is broadly used in the United States, Europe, and 
Latin America, as shown in different surveys (3), the use of 
thyroid hormones to treat NNGs is controversial, and its efficacy 
TABLe 2 | Therapeutic options for individuals with non-toxic multinodular goiter.
Treatment Advantages Disadvantages Comments
Levothyroxine Outpatient use Low efficacy Declining due to adverse effects and lack of efficacy
Low cost Main effect on perinodular volume
Prevent formation of other 
nodules?
Continuous suppression of TSH, which leads to side 
events associated with subclinical hyperthyroidism, as 
well as unpredictable bone and cardiac side effects
Surgery Substantial reduction in goiter 
size
Not applicable to all individuals
Post-surgical hemorrhage (1%)
Damage to the recurrent laryngeal nerve (1–2%)
Temporary (0.5%) or definitive (0.6%) 
hypoparathyroidism
Goiter recurrence depending on the extent of resection
Post-surgical tracheomalacia (rare)
Increased morbidity in cases with large goiters, 
intrathoracic extension or reoperation
Standard treatment for large goiters or when rapid 
decompression of cervical structures is required
Rapid relief of compression of 
vital cervical structures
Total thyroidectomy should be considered the preferred 
therapy to prevent goiter recurrence
Allows pathological assessment
Radioiodine Thyroid volume reduction by half 
in 1 year
Improves respiratory capacity in 
the long term
Frequent outpatient use
Can be successfully repeated
Few side effects
Gradual reduction in goiter size
The larger the goiter, the lower the effect
Slight risk of short-term increase in goiter size
3% risk of thyroiditis
5% risk of development of Graves’ disease
15–20% risk of hypothyroidism at 12 months
Small risk of radiation-induced ophthalmopathy
Requires retreatment in some cases
Risk of radiation-induced malignancy has not been 
established
In some European countries, radioiodine has become the 
standard therapy, replacing surgery
May be considered in place of surgical intervention in 
patients who refuse or are unable to undergo surgery, or in 
those with large goiters (except in cases that require large 
radioiodine doses)
Can be preceded by rhTSH with lower radioiodine dose
Modified and adapted from Ref. (10).
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is dependent on the degree of TSH suppression. Considering 
that NNG patients frequently have normal serum TSH levels, 
the enlargement of the thyroid in these patients is probably 
associated with the prolonged action of different growth fac-
tors (including TSH) on thyroid follicular cells with different 
synthetic and growth potentials. Advantages of this treatment 
modality include low cost, administration on an outpatient basis, 
and inhibition of the development of new nodules. In contrast, 
suppressive therapy has little effectiveness, as it requires perma-
nent treatment and may have potential undesirable effects on 
bone (demineralization) (13) and heart (arrhythmias), especially 
in older individuals (14).
In a randomized placebo-controlled trial, a ≥25% goiter 
volume reduction was seen in 58% of the individuals with NNG 
and NDG during LT4 suppressive therapy over 9 months, with a 
return to the original volume after treatment withdrawal. Over 
the same period, patients randomized to the placebo group 
showed a 20% increase in thyroid volume (15).
In another randomized trial comparing suppressive therapy 
with radioiodine, patients in the radioiodine group showed a 35% 
reduction in goiter volume at 1 year and 44% at 2 years, whereas 
those who received LT4 presented 7 and 1% reduction at 1 and 
2 years, respectively. A response to the therapy was found in 97% 
of the individuals who received radioiodine and 43% of those 
undergoing LT4 therapy (16). A recent meta-analysis showed 
lack of substantial benefits and a relative risk of only 1.9 (95% 
confidence interval, 0.95–3.81) of a decrease in nodular size 
with LT4 therapy (17). Thus, according to these randomized 
controlled trials, it seems that thyroid hormone suppression can 
interfere with the process of goitrogenesis (goiter growth and new 
nodule formation), with only some goiters responding and others 
growing despite LT4 treatment (15).
The occurrence of adverse events is more evident in older 
patients, a population that comprises most patients with NNG. 
Also, about 22% of the individuals with NNG may harbor areas 
with functional autonomy, which increase the concerns with 
LT4 therapy because of risks of bone loss and atrial fibrillation. 
Therefore, treatment with thyroid hormone should be avoided, 
especially in patients with prior serum TSH concentrations below 
the normal range.
Patients who start LT4 suppression must continue the therapy 
for a long time. The reduction in goiter size with LT4 seen in some 
individuals is probably due to decreased TSH secretion, especially 
in patients who live in areas with borderline or low iodine levels. 
Any decrease in NNG size that may occur with LT4 suppression 
is lost when the treatment is interrupted, and the nodules and 
goiter may grow again in size (15). In addition, keeping the serum 
TSH concentration in the lowest reference range or slightly below 
the normal range, rather than below 0.01 μU/mL, appears to be 
efficacious. Pending further studies, this strategy may relieve the 
adverse effects of LT4 therapy (18). Accordingly, an LT4 dose 
adjusted to obtain a non-suppressive level of serum TSH in the 
range of 0.5–0.8 μU/mL has been shown to significantly reduce 
the growth of nodules within multinodular goiters in 165 out of 
356 female patients during a follow-up period of 9 years (19).
A potential benefit of thyroid hormone therapy is a reduction 
in the risk of thyroid oncogenesis (20). However, this hypothesis 
is still speculative, and more studies are still needed.
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In general, since the volume of the thyroid reduces in only 
30% of the patients with NNGs treated with LT4 suppression, 
recommendations for this type of treatment have decreased (10).
SURGeRY
The best surgical procedure to treat patients with NNG is still 
controversial (21). A recent meta-analysis that included 1305 
participants evaluated the impact of total/near-total thyroid-
ectomy versus subtotal thyroidectomy in adults with non-toxic 
multinodular goiter. The key results of this study were (a) the 
recurrence of goiter was lower in patients who underwent thy-
roidectomy compared with those who underwent subtotal thy-
roidectomy, with rates of goiter recurrence of 84 in 1000 patients 
with subtotal thyroidectomy and 5 in 1000 patients with total 
thyroidectomy; (b) no clear benefits or harms were observed with 
subtotal or total thyroidectomy in patients undergoing surgical 
intervention due to recurrence in goiter size, complications such 
as permanent recurrent laryngeal nerve palsy, or occurrence of 
thyroid carcinoma; and (c) cancer detection was lower (6.1%) in 
patients undergoing subtotal thyroidectomy compared with 7.3% 
of those undergoing total thyroidectomy, but this difference was 
not significant (21).
In most patients with large obstructive goiters, cosmetic com-
plaints, or retrosternal NNGs for whom surgery is recommended, 
total thyroidectomy is preferable over subtotal thyroidectomy 
(22, 23). In the long term, patients undergoing subtotal thy-
roidectomy have higher recurrence rates than those undergoing 
total thyroidectomy, and 2.5–42% are required to undergo a new 
intervention. In addition, 3.5% of the NNG patients undergoing 
subtotal thyroidectomy require another surgical intervention to 
remove remaining thyroid tissue because of incidental thyroid 
carcinoma (24). Rates of permanent complications, such as 
hypoparathyroidism and vocal palsy, are similar with both total 
and subtotal surgeries; however, total thyroidectomy is preferred 
due to an increased risk of these complications associated with 
a new intervention (25). In patients with unilateral NNG, some 
authors recommend unilateral thyroidectomy based on a low rate 
of recurrence (2%) and high rate of maintenance of euthyroidism 
(73%) (26).
Post-surgical recurrence rates are directly proportional to the 
volume of the remaining thyroid tissue. Hegedüs et al. (27) stud-
ied 202 consecutive patients who underwent surgical resection 
due to benign non-toxic goiter. They found a recurrence rate of 
35% detected by ultrasonography during a median follow-up of 
10 years (27). In a retrospective study, the assessment of 112 indi-
viduals 30 years after surgery showed rates of disease recurrence 
of 40–45% during a 30-year follow-up period (28). In another 
study, the recurrence rate of the goiters was 18% when assessed 
by ultrasonography 9 years after surgery (29).
This high probability of goiter recurrence after subtotal thy-
roidectomy resulted in a preventive use of LT4. However, only one 
(30) out of four randomized trials (27, 30–32) has demonstrated 
LT4 to be effective in this setting.
A cervical incision is often used to approach intrathoracic 
goiters; however, 10–30% of the patients require sternotomy or 
thoracotomy (33).
After total thyroidectomy, patients must start LT4 replacement 
at a dose of 1.4–2.2 μg/kg/day (34). Adjustments in LT4 dose 
must be based on the patient’s age (35), according to the usual 
recommendations for patients with hypothyroidism. However, in 
patients undergoing partial thyroidectomy, treatment with LT4 
should be implemented after the establishment of hypothyroid-
ism and not preventively against goiter recurrence, because this 
benefit has not been confirmed in randomized studies (36).
The benefits and risks of a surgical procedure must be carefully 
considered, since the incidence of NNG increases with age, affect-
ing particularly elderly individuals who often have other comor-
bidities. As discussed below, rhTSH-stimulated radioiodine may 
be a treatment alternative for these patients.
THeRAPY wiTH RADiOiODiNe
Therapy with radioiodine may be recommended in cases of 
NNG affecting patients who refuse or have contraindications for 
surgery. Over the past years, this type of treatment has increased 
in patients with nodular goiter and is associated with a substantial 
decrease in glandular volume, reaching 30–40% in the first year, 
and 50–60% in the fourth year. Obstructive symptoms improve in 
most individuals (37), with reports of a single dose administered 
orally restoring euthyroidism over a period of 2–4 months (2).
Radioiodine for the treatment of goiter was introduced 
approximately three decades ago. In an initial report, 25 indi-
viduals with a mean glandular volume of 73 cm3, who received 
100 μCi of radioiodine per gram of thyroid tissue corrected to 
100% uptake in 24 h, showed an approximate reduction in goiter 
volume of 41% after 1 year of follow-up (38). The larger the vol-
ume of the gland and the lower the radioiodine uptake (RAIU), 
the higher should be the radioiodine activity to be administered. 
Subsequent studies have unanimously corroborated this observa-
tion (39, 40). Patients with very large goiters (>100  cm3) have 
a smaller decrease in glandular volume (about 35%) even with 
administration of similar radioiodine doses (37).
In some European countries such as Denmark and the 
Netherlands (to some degree), radioiodine has currently replaced 
surgery as the treatment of choice for NNG (10). Depending on 
each country’s regulations, radioiodine administered for treat-
ment purposes may be delivered in fractions on an outpatient 
basis, reducing the costs of hospitalization (41).
Some patients develop temporary mild thyrotoxicosis within 
the initial 2 weeks of treatment, and about 45% of them develop 
hypothyroidism, requiring thyroid hormone replacement for life 
(16). The occurrence of hyperthyroidism due to Graves’ disease 
associated with increased serum concentrations of TSH receptor 
antibodies has also been described in patients with increased 
baseline levels of thyroid peroxidase antibodies after radioiodine 
treatment for NNG (42).
Based on measurements of whole-body radiation exposure, 
the theoretical lifetime risk of development of cancer outside the 
thyroid gland has been calculated as 1.6%. This is due to the use of 
high doses of radioiodine in patients with very large goiters (the 
mean goiter volume used in the calculation was ~220 g). When 
administered to individuals aged 65 years or older, the estimated 
risk is ~0.5% (43).
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Recombinant Human TSH-Stimulated 
Radioiodine Therapy
Low isotope accumulation in inactive and partially suppressed 
areas around the nodule is a limitation of radioiodine treatment 
in patients with NNGs. This problem may be solved by increasing 
the RAIU in such nodular goiters (44). For this purpose, recent 
studies using rhTSH in preparation for radioiodine therapy have 
shown good results (45).
Several studies have assessed the adjuvant role of rhTSH in 
the radioiodine treatment of NNG. Administration of rhTSH is 
associated with a twofold to fourfold increase in RAIU by the 
thyroid (46). It should be noted that the baseline serum TSH may 
be a confounding factor since the increase in the 24-h thyroid 
RAIU correlates inversely with this variable. Since patients with 
NNG often present low serum TSH, the radioiodine is only taken 
up by some “hot” areas encircled by suppressed thyroid tissue that 
is inactive on scintigraphy. This phenomenon can be explained by 
a suppression of the paranodular parenchyma as a consequence 
of the low TSH level. Upon stimulation with rhTSH, these 
dormant areas, which concentrate radioiodine weakly, reactivate 
and eventually amplifies the effect of the radioiodine in the gland, 
promoting a further reduction in the volume of the goiter. In 
fact, rhTSH has been shown to distribute the radioiodine more 
homogeneously in the goiter, allowing a decrease in the dose 
of radioiodine to be administered (44). Most studies analyzing 
rhTSH in this setting have used fixed doses of radioiodine ranging 
from ~14 to ~42 mCi (37) and treatment with one or two rhTSH 
doses ranging from 0.1 to 0.3 mg administered 24 h prior to the 
radioiodine. However, the dose with ideal efficacy and safety is 
yet to be defined (47).
Combined therapy with rhTSH and radioiodine is well toler-
ated, and potential side effects that occur are similar to those 
observed in individuals receiving radioiodine alone. However, 
patients may experience a short increase in thyroid hormone 
levels within 48 h from the administration of radioiodine, lead-
ing to transient mild thyrotoxicosis, which may be followed by 
hypothyroidism during the first 30 days after the therapy (48, 49). 
Other acute adverse events that have been reported include 
painful transient thyroiditis, thyroid swelling, compression of 
the trachea, and, often, heart-related symptoms. Administration 
of glucocorticoids and β-blockers may help minimize these 
 symptoms (50).
Recent studies (37) have shown that these adverse events may 
be dependent on the dose and are negligible with lower doses of 
rhTSH. Bonnema et al. (44) have shown that the ideal rhTSH dose 
to improve treatment with radioiodine may be about 0.03–0.1 mg. 
This dose range increases the thyroid RAIU substantially, with a 
minimal risk of thyroid swelling and transient thyrotoxicosis.
Studies assessing the long-term adverse effects of the com-
bined use of rhTSH and radioiodine therapy showed an increased 
rate of permanent hypothyroidism. Three randomized controlled 
studies have reported 1-year rates of permanent hypothyroidism 
between 21 and 65% in rhTSH-pretreated patients compared with 
rates between 7 and 21% in patients in whom rhTSH was not 
administered (51–53). Due to its effect on the thyroid, rhTSH can 
potentially trigger an autoimmune response. Following treatment 
with radioiodine stimulated with rhTSH, 8 of 15 subjects with 
NNG developed antiperoxidase antibodies. However, no differ-
ences in autoimmunity were observed at 12 months between the 
subjects who underwent therapy with radioiodine alone versus 
those pretreated with rhTSH before radioiodine (54).
No studies have specifically assessed the risk of malignancy 
after NNG treatment with radioiodine with rhTSH prestimula-
tion. However, by increasing the uptake of radioiodine by the 
thyroid, rhTSH results in less radioactivity delivered to the 
thyroid and to the rest of the body, which potentially reduces the 
theoretical risk of radioiodine-induced malignancy (37).
To avoid unintentional stimulation of the thyroid, a “modi-
fied-release rhTSH” (MRrhTSH) has been recently introduced. 
This compound has a slightly different serum profile than that 
of rhTSH, with a more delayed peak and, therefore, a possible 
lower risk of goiter enlargement. A phase II study of MRrhTSH 
use in patients with NNG undergoing radioiodine therapy was 
recently published. After 6 months, patients pre-stimulated with 
MRrhTSH 0.01 mg or placebo before radioiodine therapy had a 
23% reduction in the goiter volume, whereas the reduction was 
33% in individuals pre-stimulated with MRrhTSH 0.03 mg (55).
Both rhTSH and MRrhTSH are not approved by the US Food 
and Drug Administration or European Medicines Agency to 
treat NNG in association with radioiodine; so, their use for this 
purpose is currently off-label.
An alternative approach to increase the thyroid RAIU is to 
administer methimazole to stimulate the secretion of endogenous 
TSH. Albino et  al. (56) pretreated nine patients with nodular 
goiter and subclinical hyperthyroidism with methimazole, aim-
ing at increasing the serum level of TSH above 6 μU/mL. When 
this level was achieved, radioiodine 30  mCi was administered. 
The 24-h thyroid RAIU increased from 21 to 78%, and the mean 
goiter reduction at 1 year was 46%. In eight individuals (89%) with 
subclinical hyperthyroidism, the thyroid function normalized 
after 1 year. Five patients (56%) developed overt hypothyroidism, 
and no adverse clinical events were observed. However, whether 
a marginal hypothyroid state obtained with methimazole is as 
effective as rhTSH to increase the thyroid RAIU and to augment 
the reduction in goiter size after radioiodine therapy remains to 
be clarified with controlled trials.
In summary, individuals with NDG should receive clinical 
rather than surgical treatment. NNG is a highly prevalent disease, 
even in regions without iodine deficiency. Many individuals are 
asymptomatic, and when symptoms are present, the most com-
mon clinical manifestations result from local compressive effects. 
Individuals with NDG should be thoroughly evaluated to exclude 
malignancy. They should then receive individualized therapy 
after assessment of risks and benefits of each treatment option 
and discussion with their physicians. The first therapeutic option 
is total thyroidectomy, followed by treatment with radioiodine 
alone or after rhTSH stimulation to increase the radioiodine 
efficacy.
It is unclear if suppressive therapy with thyroid hormone is 
effective in patients with NNG. The choice of this therapy has 
decreased because of concerns regarding eventual long-term side 
events due to subclinical hyperthyroidism, and due to the fact 
TABLe 3 | Circumstances of preferred thyroidectomy or radioiodine 
therapy in patients with multinodular goiter.
Radioiodine Surgery
Small or moderate goiter size ++a +
Prior thyroidectomy ++ +
Associated hyperthyroidism caused by nodular 
autonomy
++ +
Severe comorbidity ++ −
Suspicion of thyroid malignancy − ++
Very large (>100 cm3) benign goiter without 
obstructive symptoms
+b ++
Severe tracheal compression + ++
Need of rapid relief of goiter symptoms + ++
Insufficient response to previous radioiodine therapy +c ++
Retrosternal goiter or intrathoracic extension ++d +
++: first choice; +: second choice; −: no option.
aObservation may be considered in euthyroid patients with asymptomatic diffuse or 
benign nodular goiters.
bTreatment with rhTSH-stimulated radioiodine may be an option.
cA satisfactory result may be obtained with a second course of radioiodine.
dRetrosternal or intrathoracic goiters are often large, which makes surgery a preferable 
treatment.
Adapted with modifications from Ref. (44).
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after therapy interruption, most goiters grow again in size. All 
these therapies have potential advantages and disadvantages and 
are associated with short-term and long-term side events.
SURGeRY OR RADiOiODiNe THeRAPY?
Table 3 presents various circumstances associated with the devel-
opment of multinodular goiter, as well as the treatments (surgery 
or radioiodine) recommended in each case.
FiNAL ReMARKS
The therapeutic goals are to treat eventual thyroid dysfunction 
and reduce the size of the gland or prevent an additional increase 
in size. Without robust data from randomized studies, treatment 
decisions must be individualized according to the characteristics 
of the patients. Several individuals with large benign goiters 
may present symptoms of pressure, including dysphagia, neck 
tightness, or sensation of airway obstruction. Such patients fre-
quently require surgical treatment to improve their symptoms. 
Asymptomatic patients in whom malignancy is excluded may be 
only observed. Controversy remains regarding the effectiveness 
of LT4 suppression implemented to reduce the size of the goiter. 
Radioactive iodine alone or with rhTSH is safe and effective and 
may be a reasonable therapeutic option.
Finally, which is the ideal treatment for benign NDG and 
NNG goiters? Once the diagnosis and indication for treatment 
of non-toxic goiter has been made, the treating physician and 
patient should discuss each of the treatment options, including 
the benefits, side effects, expected speed of recovery, draw-
backs, and then decide on the best treatment modality for that 
particular patient, taking into account the patient’s age and 
comorbidities.
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